{"id":"NCT04031846","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Active-comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (PNEU-PED-EU-1)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-09-04","primaryCompletion":"2021-08-05","completion":"2021-08-05","firstPosted":"2019-07-24","resultsPosted":"2023-05-03","lastUpdate":"2023-07-28"},"enrollment":1184,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Infections"],"interventions":[{"type":"DRUG","name":"Rotarix™","otherNames":[]},{"type":"DRUG","name":"Infanrix™ hexa","otherNames":[]},{"type":"DRUG","name":"V114","otherNames":["VAXNEUVANCE™","Pneumococcal 15-Valent Conjugate Vaccine"]},{"type":"DRUG","name":"Prevenar 13™","otherNames":[]}],"arms":[{"label":"V114","type":"EXPERIMENTAL"},{"label":"Prevenar 13™","type":"ACTIVE_COMPARATOR"}],"summary":"This study will evaluate the safety and tolerability and immunogenicity of V114 when administered to 2-month old infants. The primary hypotheses are: 1) V114 is non-inferior to Prevenar 13™ for the 13 shared serotypes between V114 and Prevenar 13™ based on response rates at 30 days post toddler dose (PTD); 2) V114 is superior to Prevenar 13™ for the 2 serotypes unique to V114 based on the response rates at 30 days PTD; 3) V114 is non-inferior to Prevenar 13™ for the 13 shared serotypes between V114 and Prevenar 13™ based on anti-pneumococcal polysaccharide (PnPs) serotype-specific Immunoglobin G (IgG) geometric mean concentrations (GMCs) at 30 days PTD; and 4) V114 is superior to Prevenar 13™ for the 2 serotypes unique to V114 based on anti-PnPs serotype-specific IgG GMCs at 30 days PTD.","primaryOutcome":{"measure":"Percentage of Participants That Report at Least 1 Solicited Injection-site Adverse Event (AE)","timeFrame":"Up to 14 days post any vaccination (up to approximately study month 13)","effectByArm":[{"arm":"V114","deltaMin":45.3,"sd":null},{"arm":"Prevenar 13™","deltaMin":44.7,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.824"},{"comp":"OG000 vs OG001","p":"= 0.324"},{"comp":"OG000 vs OG001","p":"< 0.001"},{"comp":"OG000 vs OG001","p":"= 0.128"}]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":16},"locations":{"siteCount":60,"countries":["Australia","Belgium","Czechia","Estonia","Germany","Greece","Poland","Russia","Spain"]},"refs":{"pmids":["37105892"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":57,"n":587},"commonTop":["Irritability","Injection site erythema","Somnolence","Pyrexia","Injection site induration"]}}